Symptom management
FDA approval of bevacizumab biosimilar
On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic...
Dexamethasone for dysnea treatment
Patients with cancer often suffer shortness of breath for different reasons. Many physicians prescribe empirical dexamethasone as a symptomatic treatment....
.png)